Barchart on Facebook
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Genmab A/S (GMAB)

Genmab A/S (GMAB)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 22,904,756
  • Shares Outstanding, K 654,983
  • Annual Sales, $ 804,360 K
  • Annual Income, $ 324,680 K
  • 60-Month Beta 0.85
  • Price/Sales 28.47
  • Price/Cash Flow 65.84
  • Price/Book 8.66
Trade GMAB with:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/20
See More
  • Average Estimate 0.08
  • Number of Estimates 5
  • High Estimate 0.10
  • Low Estimate 0.07
  • Prior Year 1.26
  • Growth Rate Est. (year over year) -93.65%

Price Performance

See More
Period Period Low Period High Performance
1-Month
33.68 +0.30%
on 10/28/20
38.50 -12.26%
on 10/14/20
-3.17 (-8.58%)
since 09/28/20
3-Month
33.68 +0.30%
on 10/28/20
38.87 -13.09%
on 09/18/20
-1.48 (-4.20%)
since 07/28/20
52-Week
16.24 +108.01%
on 03/16/20
38.87 -13.09%
on 09/18/20
+12.46 (+58.44%)
since 10/28/19

Most Recent Stories

More News
4 Innovative Biotech Stocks That Could Dominate Healthcare in 2021

Aging population, lifestyle changes and pandemics have created a huge demand for patient-focused healthcare. Biotech stocks like Seagen (SGEN), Genmab A/S (GMAB), Amedisys (AMED), and Masimo (MASI) could...

SGEN : 195.93 (-0.50%)
GMAB : 33.90 (-3.06%)
MASI : 238.81 (-4.92%)
AMED : 249.80 (-2.27%)
4 Top Biotech Stocks to Buy for the Remainder of 2020

With huge investments being made in biotech thanks to the pandemic, there has been a renewed focus on biotech stocks. Here are four worth considering: Amgen (AMGN), Immunomedics (IMMU), Seattle Genetics...

AMGN : 217.22 (-2.79%)
SGEN : 195.93 (-0.50%)
GMAB : 33.90 (-3.06%)
IMMU : 87.86 (+0.05%)
4 Game-Changing Biotech Stocks to Buy Right NOW!

Amgen (AMGN), Genmab A/S (GMAB), Seattle Genetics (SGEN), and Alexion Pharmaceuticals (ALXN) are leading biotech companies engaged in developing cancer drugs. As the number of cancer patients rises with...

AMGN : 217.22 (-2.79%)
SGEN : 195.93 (-0.50%)
ALXN : 115.88 (-3.43%)
GMAB : 33.90 (-3.06%)
Is Moderna a Good Coronavirus Stock to Buy?

Moderna (MRNA) is one of the leading biotech manufacturers in the race to develop a coronavirus vaccine. The stock seems overvalued by traditional measures, but the company’s unique approach to developing...

MRNA : 67.10 (-5.05%)
AMGN : 217.22 (-2.79%)
GMAB : 33.90 (-3.06%)
ALXN : 115.88 (-3.43%)
Seattle Genetics and Genmab Present Data from Tisotumab Vedotin innovaTV 204 Pivotal Trial in Recurrent or Metastatic Cervical Cancer at ESMO Virtual Congress 2020

--- Biologics License Application Submission Planned to Support Accelerated Approval Pathway with the FDA -

SGEN : 195.93 (-0.50%)
GMAB : 33.90 (-3.06%)
4 Healthcare Stocks with HIGH Profit Margins

Healthcare players such as Regeneron Pharmaceuticals (REGN), Genmab (GMAB), Horizon Therapeutics (HZNP), and Bio-Rad Laboratories (BIO) demonstrated high-profit margins and are expected to witness a surge...

REGN : 567.31 (-2.61%)
GMAB : 33.90 (-3.06%)
HZNP : 75.57 (-3.30%)
BIO : 568.38 (-3.59%)
Seattle Genetics (SGEN) to Receive Milestone Fee from Glaxo

Seattle Genetics (SGEN) to win a milestone fee from GlaxoSmithKline following the EU approval of Blenrep, developed by the latter. Blenrep is made using the company's proprietary technology.

GSK : 34.23 (-3.17%)
EBS : 92.27 (-2.76%)
SGEN : 195.93 (-0.50%)
GMAB : 33.90 (-3.06%)
AbbVie Outperforms Large-Cap Pharma Industry Year to Date

AbbVie's (ABBV) key drug, Humira is seeing strong demand in the United States while generics are eroding ex-U.S. sales. New drugs Skyrizi and Rinvoq are seeing strong sales uptake.

RHHBY : 40.2560 (-2.31%)
NVS : 79.03 (-2.37%)
ABBV : 80.45 (-2.73%)
GMAB : 33.90 (-3.06%)
Genmab (GMAB) to Report Q2 Earnings: What's in the Cards?

Genmab's (GMAB) second-quarter revenues are likely to have been driven by royalties on sales of J&J's Darzalex. Several pipeline candidates are under development.

JNJ : 139.14 (-2.80%)
NVS : 79.03 (-2.37%)
ACRX : 1.7600 (+0.57%)
GMAB : 33.90 (-3.06%)
Can Genmab AS Sponsored ADR (GMAB) Run Higher on Rising Earnings Estimates?

Genmab AS Sponsored ADR (GMAB) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

GMAB : 33.90 (-3.06%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Buy with a Weakening short term outlook on maintaining the current direction.

See More Share

Business Summary

Genmab A/S is a biotechnology company. It specializes in development of antibody therapeutics for the treatment of cancer. The company's product pipeline includes DARZALEX(R), Arzerra(R), tisotumab vedotin, enapotamab vedotin, HexaBody-DR5/DR5(R) and DuoBody-CD3xCD20 (R),which are in clinical stage....

See More

Key Turning Points

2nd Resistance Point 35.51
1st Resistance Point 35.24
Last Price 33.90
1st Support Level 34.73
2nd Support Level 34.49

See More

52-Week High 38.87
Last Price 33.90
Fibonacci 61.8% 30.23
Fibonacci 50% 27.56
Fibonacci 38.2% 24.88
52-Week Low 16.24

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar